FindTrial
Sign In

Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)

DRUG2 trials

Sponsors

AMAG Pharmaceuticals, Inc.

Conditions

Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) in Healthy Post-menopausal WomenComparing Bioavailability When Makena® is Administered in Healthy Post-menopausal Women

Phase 1

Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women
CompletedNCT02940522
AMAG Pharmaceuticals, Inc.Comparing Bioavailability When Makena® is Administered in Healthy Post-menopausal Women
Start: 2016-09-30End: 2017-03-31Updated: 2022-04-28

Phase 3

Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women
TerminatedNCT02937766
AMAG Pharmaceuticals, Inc.Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) in Healthy Post-menopausal Women
Start: 2016-10-07End: 2017-03-27Updated: 2022-04-21

Related Papers

Comparative Bioavailability of Hydroxyprogesterone Caproate Administered via Intramuscular Injection or Subcutaneous Autoinjector in Healthy Postmenopausal Women: A Randomized, Parallel Group, Open-label Study
Clinical Therapeutics2017-11-287 citations